Breaking News

CPR Pharma Expands APAC Capabilities

March 26, 2013

Adds bioanalytical assay services

CPR Pharma Services has expanded it services in the Asia-Pacific region with a new lab in Adelaide, Australia that offers ligand binding assay services for biomarkers, monoclonal antibodies, biosimilars and biologics for early and late phase development. 
 
The new large molecule immunochemistry analytical service will be run by John Chappell, an expert in ligand binding assay development, validation and implementation. Mr. Chappell is a member of the AAPS Committee and has more than 20 years of CRO experience having held positions with Covance, ClinTrials BioResearch, BAS Analytics, Veeda and ICON. 
 
CPR’s chief executive officer, Jason Valentine, said, “John’s appointment with CPR will bring unparalleled expertise in biologic and biosimilar assay development and validation to the Asia/Pacific region. Monoclonal antibodies, proteins, biologics and biosimilars are the new growth areas in drug development and will progressively occupy a larger share of drugs developed globally. Couple this with the increased emphasis on biomarker monitoring in clinical trials and large molecule quantification is critical to any modern bioanalysis laboratory.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems